Health
-
FDA panel backs Amgen copy of AbbVie arthritis drug Humira
Jul 13, 2016News Hour: Amgen Inc’s cheaper version of AbbVie’s top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The... -
AIDS conference returns to a changed South Africa
Jul 13, 2016News Hour: The South Africa that hosts a global AIDS Conference next week has come a long way from the “AIDS pariah” that did so 16 years ago, when then President Thabo Mbeki stunningly dismissed the... -
AstraZeneca resolves Faslodex patent litigation in U.S.
Jul 13, 2016News Hour: British drugmaker AstraZeneca Plc said on Wednesday it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG, to resolve Faslodex patent litigation in the U.S. The company said it... -
Takeda announces support to japan voluntary organizations active in disaster (jvoad)
Jul 12, 2016News Hour: The Japan Voluntary Organizations Active in Disaster (JVOAD) Preparatory Committee (Representative: Nobuyuki Kurita) held a founding meeting of the JVOAD on June 7, 2016, in aiming to incorporate as a specified non-profit organization. Takeda... -
Tri-Institutional therapeutics discovery institute, inc. expands partnership with Takeda pharmaceutical company, ltd.
Jul 12, 2016News Hour: Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013... -
Takeda and m2gen collaborate with orien to speed clinical development and discovery of cancer treatments through health informatics
Jul 12, 2016News Hour: Takeda Pharmaceutical Company Limited and M2Gen®, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology... -
Giving children in long-term treatment the energy to live announcement of the recipient projects
Jul 12, 2016News Hour: Takeda Pharmaceutical Company Limited announced the decision for three projects to be subsidized in the second year (October 2015 to September 2016) of the Civil Society Initiative Subsidy Program « Takeda Well-Being Program II : Giving... -
Examine trial post-hoc analyses of mortality data regarding cardiovascular safety of alogliptin presented at american diabetes association’s 76th scientific sessions
Jul 12, 2016News Hour: Takeda Pharmaceutical Company Limited, (“Takeda”) announced the publication of a post-hoc analysis from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute... -
Takeda licenses global rights to theravance biopharma’s td-8954, a novel 5-ht4 agonist and motility agent
Jul 12, 2016News Hour: Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) announced that the companies have entered into a global license, development and commercialization agreement for TD-8954, a selective 5-HT4... -
Ultragenyx and takeda enter into a collaboration to develop and commercialize therapies for rare genetic diseases
Jul 12, 2016News Hour: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare genetic diseases, and Takeda Pharmaceutical Company Limited, announced a strategic partnership to develop and commercialize...
